skye-bioscience-inc.

Skye Bioscience Inc. Company Profile

Background

Skye Bioscience Inc. is a clinical-stage biotechnology company headquartered in San Diego, California. Established in 2011, the company focuses on developing innovative treatments for obesity and related metabolic disorders by targeting G-protein-coupled receptors (GPCRs). Its lead product candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1), a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.

Key Strategic Focus

Skye Bioscience's strategic focus is on developing novel therapies that modulate GPCRs to address unmet needs in obesity and metabolic diseases. The company's core objectives include:

• Developing Nimacimab: Advancing nimacimab through clinical trials to assess its efficacy and safety as a treatment for obesity and related metabolic conditions.

• Exploring Combination Therapies: Investigating the potential of combining nimacimab with other treatments, such as GLP-1 receptor agonists, to enhance therapeutic outcomes.

• Expanding Clinical Trials: Conducting comprehensive clinical studies to gather robust data supporting the therapeutic potential of nimacimab.

The company specializes in antibody-based therapies targeting CB1 receptors, utilizing proprietary technologies to develop treatments with favorable safety profiles. Primary markets include the United States and other regions with high obesity prevalence.

Financials and Funding

Skye Bioscience has raised approximately $107 million in capital since mid-2023, with key investors including 5AM Ventures. The most recent funding round, a post-IPO offering, occurred on March 13, 2024, raising $40 million. The capital is intended to fund projected operations and key clinical milestones into 2027.

Pipeline Development

The company's lead pipeline candidate, nimacimab, is undergoing a Phase 2a clinical trial named CBeyond™. The trial is assessing nimacimab as a monotherapy and in combination with semaglutide, a GLP-1 receptor agonist. Topline data from the initial 26-week period were reported in October 2025, indicating that while nimacimab alone did not meet the primary endpoint for weight loss, the combination therapy showed meaningful additional weight loss compared to semaglutide alone. The study is continuing with a 26-week extension to provide 52 weeks of treatment and 13 weeks of follow-up.

Technological Platform and Innovation

Skye Bioscience's proprietary technology centers on nimacimab, a monoclonal antibody that inhibits peripheral CB1 receptors. This approach aims to modulate metabolic processes without central nervous system side effects associated with earlier CB1 inhibitors. The company's scientific methodology includes:

• Antibody Development: Designing antibodies that specifically target peripheral CB1 receptors to influence metabolic regulation.

• Clinical Trial Design: Implementing robust clinical trial protocols to evaluate the safety and efficacy of nimacimab in diverse patient populations.

• Combination Therapy Exploration: Investigating the synergistic effects of nimacimab combined with other metabolic regulators, such as GLP-1 receptor agonists.

Leadership Team

Skye Bioscience's leadership team comprises experienced professionals with extensive backgrounds in biotechnology and pharmaceuticals:

• Punit S. Dhillon, B.A. – President, Chief Executive Officer, Principal Accounting Officer, and Director: With over 20 years in the life sciences industry, Mr. Dhillon has raised more than $500 million in capital and established multiple pharmaceutical partnerships. He previously co-founded and served as CEO of OncoSec Medical.

• Tu Diep, M.Sc. – Chief Operating Officer: Mr. Diep brings over 15 years of scientific, clinical research, and operational experience. He was a founding employee of OncoSec Medical Inc., where he led the development of the company's lead program and spearheaded a clinical collaboration with Merck.

• Dr. Christopher G. Twitty, Ph.D. – Chief Scientific Officer: Dr. Twitty has over 25 years of life science research and drug development experience. He has led R&D and translational efforts to expand drug pipelines and has supported multiple IND filings for novel therapeutics.

• Dr. Puneet S. Arora, M.D., M.S., FACE – Chief Medical Officer: Dr. Arora is a board-certified physician in endocrinology, diabetes, and metabolism, with over 15 years of experience in clinical trials, regulatory submissions, and medical affairs in biotech and pharma.

Leadership Changes

As of April 2026, there have been no significant changes or appointments within Skye Bioscience's leadership team.

Competitor Profile

Market Insights and Dynamics:

The global obesity treatment market is experiencing significant growth, with projections estimating it will exceed $100 billion by 2030. This expansion is driven by increasing obesity rates and the demand for effective weight loss therapies.

Competitor Analysis:

Skye Bioscience operates in a competitive landscape with several companies developing treatments for obesity and metabolic disorders. Notable competitors include:

• Endogena: A private company founded in 2016, focusing on biotechnology solutions for metabolic diseases.

• Certa Therapeutics: Established in 2018, this company specializes in developing therapies for metabolic and inflammatory conditions.

• Cincera Therapeutics: A biotechnology firm concentrating on treatments for metabolic disorders.

These competitors are actively developing therapies targeting metabolic pathways, contributing to the dynamic and evolving market landscape.

Strategic Collaborations and Partnerships

In January 2026, Skye Bioscience announced a global collaboration and license agreement with Halozyme Therapeutics, Inc. to evaluate nimacimab co-formulated with ENHANZE® for obesity. This partnership aims to develop higher-dose, subcutaneous administration strategies for nimacimab, potentially enhancing its therapeutic efficacy and patient convenience.

Operational Insights

Skye Bioscience's strategic considerations include:

• Clinical Development: Advancing nimacimab through clinical trials to establish its safety and efficacy profile.

• Market Positioning: Differentiating nimacimab from existing therapies by targeting peripheral CB1 receptors to minimize central nervous system side effects.

• Regulatory Strategy: Navigating regulatory pathways to achieve approvals in key markets, including the United States and Europe.

These strategies position Skye Bioscience to effectively compete in the obesity treatment market.

Strategic Opportunities and Future Directions

Skye Bioscience's strategic roadmap includes:

• Expanding Clinical Trials: Conducting additional studies to further validate nimacimab's efficacy and safety.

• Exploring Combination Therapies: Investigating the potential of combining nimacimab with other metabolic regulators to enhance therapeutic outcomes.

• Global Market Expansion: Pursuing regulatory approvals and partnerships to introduce nimacimab into international markets.

These initiatives leverage the company's strengths in antibody-based therapies and its focus on metabolic diseases to achieve future objectives.

Contact Information

• Website: Skye Bioscience official website.

• Social Media:

• LinkedIn: Skye Bioscience company profile.

• Twitter: Skye Bioscience official account.

Skye Bioscience's commitment to developing innovative therapies for obesity and metabolic disorders underscores its role in addressing significant health challenges through scientific advancement and strategic partnerships.